Real-world effectiveness and safety of dupilumab for the treatment of moderate to severe atopic dermatitis in Indian patients: A multi centric retrospective study

Introduction: Treatment of moderate to severe atopic dermatitis (AD) is a real challenge for the dermatologists. Dupilumab is the first targeted biologic therapy approved for the treatment of children and adults with moderate-to-severe AD. The efficacy and safety of dupilumab in Indian patients is l...

Full description

Bibliographic Details
Main Authors: Sandipan Dhar, Abhishek De, Sahana M Srinivas
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Indian Journal of Dermatology
Subjects:
Online Access:http://www.e-ijd.org/article.asp?issn=0019-5154;year=2021;volume=66;issue=3;spage=297;epage=301;aulast=Dhar